A Phase I Study of Ceritinib (LDK378), a Novel ALK Inhibitor, in Combination With Gemcitabine-Based Chemotherapy in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Ceritinib (Primary) ; Cisplatin; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- 20 Feb 2018 Planned primary completion date changed from 11 Feb 2018 to 11 May 2018.
- 26 Dec 2017 Planned primary completion date changed from 11 Dec 2017 to 11 Feb 2018.
- 05 Oct 2017 Planned primary completion date changed from 11 Sep 2017 to 11 Dec 2017.